<DOC>
	<DOCNO>NCT02628132</DOCNO>
	<brief_summary>The expression PD-L1 breast cancer previously demonstrate ( Ghebeh et al 2006 ) . In addition , PD-L1 show work `` molecular shield '' , protect cancer cell cytotoxic T-cells chemotherapy induce apoptosis ( Ghebeh et al 2008 ) suggest combine PD-L1 blockade chemotherapy . This trial test Durvalumab combination Paclitaxel metastatic triple-negative breast cancer patient . The safety profile Durvalumab monotherapy previously establish ( lu et al 2015 ) . In trial safety profile tolerability Durvalumab give combination Paclitaxel test . In addition , efficacy combination metastatic breast cancer monitor .</brief_summary>
	<brief_title>Study Safety Efficacy Durvalumab Combination With Paclitaxel Metastatic Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>This open label single arm trial involve metastatic triple negative PD-L1 positive breast cancer patient . The trial include dose de-escalation phase three dos paclitaxel tried 3 patient follow dose expansion phase 25 patient . Paclitaxel give weekly 2 cycle follow combination Paclitaxel Durvalumab . Once 6 cycle Paclitaxel complete , Durvalumab give alone disease progression unacceptable toxicity . The toxicity tolerability two combination main end point efficacy secondary end point .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Confirmed metastatic breast cancer 2 . Triple negative breast cancer ( estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative Her2/neu negative ) . 3 . Patients receive least 1 line chemotherapy metastatic setting enrol trial . 4 . Histologically confirm PDL1 positive breast cancer 5 . Written inform consent locallyrequired authorization 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 7 . Life expectancy &gt; 12 week 8 . Adequate normal organ marrow function . 1 . Involvement plan and/or conduct study previous enrolment present study 2 . Participation another clinical study investigational product last 4 month 3 . Any previous treatment PD1 PDL1 inhibitor , include MEDI4736 CTLA 4 inhibitor 4 . Mean QT interval correct heart rate ( QTc ) â‰¥470 m calculate 3 electrocardiogram ( ECGs ) use Frediricia 's Correction 5 . Current prior use immunosuppressive medication within 28 day first dose MEDI4736 , exceptions 10 mg dexamethasone prior paclitaxel infusion intranasal inhale corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid 6 . Active prior document autoimmune disease within past 2 year 7 . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) 8 . History primary immunodeficiency 9 . History allogeneic organ transplant 10 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , interstitial lung disease ( ILD ) , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent 11 . Known history previous clinical diagnosis tuberculosis 12 . History leptomeningeal carcinomatosis 13 . Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive MEDI4736 14 . Female subject pregnant , breastfeed male female patient reproductive potential employ effective method birth control 15 . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result 16 . Symptomatic uncontrolled brain metastasis require concurrent treatment , inclusive limited surgery , radiation and/or corticosteroid . 17 . Subjects uncontrolled seizure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>triple negative</keyword>
	<keyword>breast cancer</keyword>
	<keyword>durvalumab</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PD-1</keyword>
	<keyword>Metastatic</keyword>
	<keyword>AstraZeneca</keyword>
	<keyword>MEDI4736</keyword>
</DOC>